Bc Cancer Chemotherapy Preparation and Stability

Home , Amsacrine, Azacitidine, Belantamab mafodotin, Belinostat, Bendamustine, Bleomycin

record time of reconstitution

Aldesleukin 22 million units 1.2 mL SWI4 18 million unit/mL 48 h F, RT4 30-70 mcg/mL4 48 h F, RT4 - do NOT use in- (1.3 mg) (1.1 mg/mL)4 line filter4 (SteriMax) direct diluent against 50 mL D5W4 - avoid (F)(PFL) side of vial during bacteriostatic water no preservative4 reconstitution4 <30 mcg/mL: for injection or NS dilute in D5W due to increased do NOT shake4 containing human aggregation4 albumin 0.1%5 - bring to room temperature prior to infusion4 SC syringe6,7 14 d F7

**(PFL)

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 1/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability (for IV bag size selection, Precautions/Notes Manufacturer, Preservative see Notes†) Status) Aldesleukin intralesional 1.2 mL SWI4 18 million unit/mL 48 h F, RT4 add 3.2 mL D5W syringe: - avoid 22 million units (1.1 mg/mL)4 to reconstituted vial 48 h F8 bacteriostatic water (1.3 mg) direct diluent against to give (discard any remaining for injection or NS (SteriMax) side of vial during 5 million units/mL8,9 unused syringes due to increased (F)(PFL) reconstitution4 following procedure) aggregation4 no preservative4 withdraw entire do NOT shake4 contents of vial into syringes for administration8,10

Alemtuzumab 30 mg/mL N/A filter NOT discard unused SC syringe13 discard at the end of - do NOT shake14 (Genzyme/Bayer)11 required12 portion12 the day F, RT (F)(PFL) 12 do not shake 30 mg/mL 12 no preservative 100 mL 8 h F, RT12 12 NS, D5W **(PFL)14

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 2/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

mix by gentle inversion15

Amsacrine 75 mg/1.5 mL glass syringes 5 mg/mL16 24 h RT16 500 mL D5W16 7 d F, 48 h RT16-18 - contains DMA*** (Erfa Canada) preferred during (RT) reconstitution; **(PFL)16 (plastic or glass no preservative16 max. time in plastic container)16 syringe16: 15 min

13.5 mL supplied diluent (L-lactic acid)1

transfer 1.5mL from ampoule into the diluent vial16

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 3/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Erwinia asparaginase (asparaginase Erwinia 1-2 mL NS20 10,000-5000 15 min RT20 syringe20 4 h RT20 - contact with the chrysanthemi) units/mL rubber stopper may 10,000 units do not shake; mix denature the (CGF/Jazz) gently to minimize reconstituted drug, (F) bubbles and contact creating filaments no preservative20 with stopper20 of insoluble material; if present, administer with 5 micron filter20 - do not use sterile water for reconstitution as the resulting product is not isotonic20

PEG-asparaginase - see pegaspargase in L-Z chart (pegylated asparaginase E. coli)

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 4/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Avelumab 200 mg/10 mL N/A 20 mg/mL22 discard unused 250 mL complete - do NOT shake22 (EMD) portion23 NS, ½-NS22 administration within - administer with (F)(PFL) 24 h F, 8 h RT22 0.2 micron in-line no preservative22 if refrigerated, mix by gentle filter22 bring vial to RT inversion22 if refrigerated, bring prior to use22 bag to RT prior to administration22

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 5/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability (for IV bag size selection, Precautions/Notes Manufacturer, Preservative see Notes†) Status) azaCITIDine 100 mg 4 mL SWI24 25 mg/mL24 45 min RT, SC syringe24 45 min RT (including - discard if contains (Celgene) 8 h F24 preparation time), large particles24 (RT) shake vigorously24 8 h F24 - re-suspend no preservative24 syringe contents record time of refrigerate syringe before injection by reconstitution immediately after vigorously rolling preparation if not to be syringe between used within 45 min of palms24 reconstitution25 -if cold diluent reconstitution is Refrigerated used to extend syringes24: stability, minimize  allow up to 30 min exposure to RT; prior to administration ensure proper to reach a refrigeration of temperature of diluent, ~20-25°C reconstituted vial,  discard syringe if and final product time elapsed at RT is greater than 30 min

cold diluent 25 mg/mL24 22 h F26,27 22 h F26,27 reconstitution: 4 mL SWI at 2- 8°C26,27

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 6/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Refrigerated syringes28:  allow up to 30 min prior to administration to reach a temperature of ~20-25°C  discard syringe if time elapsed at RT is greater than 30 min

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 7/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability (for IV bag size selection, Precautions/Notes Manufacturer, Preservative see Notes†) Status) BCG (Tice substrain) 1 mL preservative- 1 to 8×108 2 h F29 transfer from vial to use within 2 h F of - auxiliary info: intravesical free NS29 CFU/vial29 60 mL syringe, rinse reconstitution29,30 biohazard30 50 mg = 1 to 8 x 108 **(PFL)29 vial with another 1 mL - do NOT filter29 CFU allow to stand for a NS; add rinse to **(PFL)29 - do NOT shake29 (Merck Canada) few minutes, then same 60 mL syringe (F)(PFL) gently swirl to and qs to 50 mL with no preservative29 suspend29 NS29

record time of if a closed system reconstitution transfer device is used: transfer from vial to 60 mL syringe and qs to 50 mL with NS; do NOT rinse vial29

BCG (Tice substrain) 1 mL preservative 1 to 8×108 2 h F31 transfer from vial to use within 2 h F of - auxiliary info: intravesical free NS31 CFU/vial31 60 mL syringe and qs reconstitution30,31 biohazard30 50 mg = 1 to 8 x 108 **(PFL31 to 50 mL with NS31 - do NOT filter31 CFU allow to stand for a **(PFL)31 - do NOT shake31 (Merck USA) few minutes, then (F)(PFL) gently swirl to no preservative31 suspend31

record time of reconstitution

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 8/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

record time of reconstitution

Belantamab mafodotin 30 mg/1.5 mL n/a 20 mg/mL33 thaw up to 4 h 0.2-2 mg/mL NS33 8 h RT33 - supplied as (GSK) RT, F before frozen liquid33 (frozen)(PFL) use33 250 mL* NS33 - recommended do not shake freezer temp33 is (- no preservative33 once thawed: 50°C to -15°C) unpunctured - thawed drug vial: cannot be 10 d F33 refrozen33

once thawed: punctured vial: discard unused portion30,33

**(PFL)33

do NOT shake33

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 9/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Belinostat 500 mg 9 mL SWI36 50 mg/mL36 12 h RT36 250 mL NS36 complete - administer with (Spectrum) administration within 0.2 micron in-line (RT) 36 h RT36 filter36 no preservative36

Bendamustine 25 mg 25 mg vial: 5 mg/mL37 30 minutes37 0.2-0.6 mg/mL complete 100 mg 5 mL SWI37 NS, D2.5-½NS37 administration within (Lundbeck/Teva) 24 h F, 3 h RT38 (RT,F)(PFL) 100 mg vial: 250-500 mL† no preservative37 20 mL SW37

shake well; dissolves completely in 5 minutes37

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 10/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Bevacizumab (MVASI®) N/A 25 mg/mL40 discard unused 1.4-16.5 mg/mL 48 h F, RT40 - do NOT shake40 100 mg/4 mL portion40 NS only40 400 mg/16 mL (Amgen) 100-250 mL† (F)(PFL) do not shake no preservative40

Bevacizumab (ZIRABEV®) N/A 25 mg/mL41 discard unused 1.4-16.5 mg/mL 48 h F, RT41 - do NOT shake41 100 mg/4 mL portion41 NS only41 400 mg/16 mL (Pfizer) 100-250 mL† (F)(PFL) do not shake no preservative41

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 11/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Bleomycin 15 units 6 mL* NS, SWI43 2.5 units/mL 48 h F, 24 h RT43 50 mL* NS43 4 h RT30,43 (NB: dose in units only) (Pfizer/Hospira) (F)(PFL) no preservative43

Blinatumomab 38.5 mcg 3 mL SWI44 12.5 mcg/mL44 24 h F, 4 h RT44 250 mL NS44 complete - use non-DEHP (Amgen) administration within bag and IV (F)(PFL) do NOT use add supplied IV 10 d F, 96 h RT44 administration set44 do not shake supplied IV solution solution stabilizer to - administer with no preservative44 stabilizer to NS bag and gently 0.2 micron in-line reconstitute vials44 mix to avoid filter44 foaming44 - prime lines with direct diluent against blinatumomab side of vial during add reconstituted solution; do NOT reconstitution44 drug to bag following use NS addition of IV solution gently swirl to avoid stabilizer44 excess foaming44

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 12/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Bortezomib 3.5 mg 3.5 mL NS45 1 mg/mL45 2 d F, RT46,47 IV syringe45 14 d F, 48 h RT46,47 - auxiliary info: (Actavis) WARNING: (RT)(PFL) INTRAVENOUS no preservative45 use only. Fatal if given by other routes.

Bortezomib SC injection 1.4 mL NS48 2.5 mg/mL48 2d F, RT30,49 SC syringe48 14 d F, 48 h RT30,49 - auxiliary info: 3.5 mg WARNING: (Apotex) SUBCUTANEOUS (RT)(PFL) use only. Fatal if no preservative48 given by other routes.

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 13/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Bortezomib SC injection 1.4 mL NS50 2.5 mg/mL50 2 d F, RT46,47 SC syringe50 14 d F, 48 h RT46,47 - auxiliary info: 3.5 mg WARNING: (Janssen) SUBCUTANEOUS (RT)(PFL) use only. Fatal if no preservative50 given by other routes.

Bortezomib 3.5 mg 3.5 mL NS50 1 mg/mL50 2 d F, RT46,47 IV syringe50 14 d F, 48 h RT46,47 - auxiliary info: (Janssen) WARNING: (RT)(PFL) INTRAVENOUS no preservative50 use only. Fatal if given by other routes.

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 14/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Bortezomib 1 mg 1 mg vial: 1 mg/mL51 2 d F, RT30,52 IV syringe51 14 d F, 48 h RT30,52 - auxiliary info: 2.5 mg 1 mL NS51 WARNING: 3.5 mg INTRAVENOUS (Juno/MDA) 2.5 mg vial: use only. Fatal if (RT)(PFL) 2.5 mL NS51 given by other no preservative51 routes. 3.5 mg vial: 3.5 mL NS51

Bortezomib SC injection 1.4 mL NS53 2.5 mg/mL53 2 d F, RT46,47 SC syringe53 14 d F, 48 h RT46,47 - auxiliary info: 3.5 mg WARNING: (Teva) SUBCUTANEOUS (RT)(PFL) use only. Fatal if no preservative53 given by other routes.

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 15/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Brentuximab vedotin 50 mg 10.5 mL SWI54 5 mg/mL54 24 h F54 0.4-1.8 mg/mL 24 h F54 - solution should be (GMD/Seattle Genetics) NS, D5W, Lactated clear to slightly (F)(PFL) direct diluent against Ringer’s opalescent, no preservative54 side of vial during colorless, and free reconstitution54 100 mL† of visible particulates54 do NOT shake54

Busulfan 60 mg/10 mL N/A 6 mg/mL55 discard unused dilute to volume complete - contains DMA*** (PMS) portion30,55 10 times drug volume administration within - always add (F) to achieve final 12 h F, 8 h RT55 busulfan to diluent no preservative55 concentration of to mix; do not add ~0.5 mg/mL diluent to NS, D5W55 busulfan55

250-1000 mL†

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 16/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Cabazitaxel 45 mg/4.5 mL N/A 10 mg/mL57 10 d F, RT57 0.10-0.26 mg/mL complete - use non-DEHP 60 mg/6 mL NS, D5W57 administration within bag and tubing57 (Sandoz) 48 h F, 8 h RT57 - administer with (RT) 100-250 mL† 0.2 micron in-line preservative57 filter57 - vials contain overfill57

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 17/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability (for IV bag size selection, Precautions/Notes Manufacturer, Preservative see Notes†) Status) Cabazitaxel 60 mg/1.5 mL supplied diluent: 10 mg/mL58 1 h RT58 0.10-0.26 mg/mL complete - use non-DEHP (sanofi-aventis) withdraw entire NS, D5W58 administration within bag and tubing58 (RT) contents of diluent 48 h F, 8 h RT58 - administer with no preservative58 vial and inject into 100-250 mL† 0.2 micron in-line the concentrate filter58 vial58 - concentrate and diluent vials slowly direct diluent contain overfill58 against inside of vial - diluent contains to limit foaming58 13% (w/w) ethanol in water58 mix by repeated - discard if inversions for 45 crystallization sec58 occurs58

do NOT shake58

let sit for 5 min58

CARBOplatin 50 mg/5 mL N/A 10 mg/mL59 discard unused 0.5-10 mg/mL 24 h F, 8 h RT59 - do NOT use 150 mg/15 mL portion59 NS, D5W59 aluminum- 450 mg/45 mL containing needle, 600 mg/60 mL 100-250 mL† syringe, or tubing59 (Accord) (RT)(PFL) no preservative59

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 18/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

CARBOplatin 50 mg/5 mL N/A 10 mg/mL62 discard unused 0.3-10 mg/mL 48 h F62 - do NOT use 150 mg/15 mL portion62 NS, D5W62 aluminum- 450 mg/45 mL containing needle, 600 mg/60 mL 100-250 mL† syringe, or tubing62 (Pfizer/Hospira) (RT)(PFL) no preservative62

CARBOplatin 50 mg/5 mL N/A 10 mg/mL63 discard unused 0.5-10 mg/mL64 8 h RT63 - do NOT use 150 mg/15 mL portion RT63 NS, D5W63,65,66 aluminum- 450 mg/45 mL containing needle, (Teva/Novopharm) 100-250 mL† syringe, or tubing63 (RT)(PFL) no preservative63

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 19/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

direct diluent against side of vial during reconstitution67

swirl gently; do NOT shake67

if foaming occurs, allow to settle until clear (about 5 minutes)67

record time of reconstitution

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 20/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

record time of reconstitution

Cemiplimab 250 mg/5 mL N/A 50 mg/mL71 discard unused 1-20 mg/mL complete - administer with 350 mg/7 mL portion30,71 NS, D5W71 administration within 0.2 micron filter71 (sanofi) 24 h F, 8 h RT71 - solution may (F)(PFL) 50 mL† contain white do not shake particulates which no preservative71 mix by gentle do not affect inversion product quality71

Cetuximab 100 mg/50 mL N/A 2 mg/mL72 12 h F, 8 h RT72 syringe72 12 h F, 8 h RT72 - administer with 200 mg/100 mL 0.2 micron filter72 (Imclone/Lilly) - solution may (F) evacuated container contain white do not shake or bag72 particulates which no preservative72 do not affect product quality72

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 21/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

CISplatin 50 mg/50 mL N/A 1 mg/mL74 discard unused NS74 24 h RT74 - do NOT use 100 mg/100mL portion30 aluminum- (Pfizer/Hospira) 100-500 mL† containing needle, (RT)(PFL) syringe or tubing74 no preservative74 or 2 L D5-½NS or - suggested dose D5-⅓NS limits relate to the containing 37.5 g physical limitations of mannitol74 of the bag size and added drug volume; it is not a concentration- dependent property of the drug

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 22/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

CISplatin 10 mg/10 mL N/A 1 mg/mL77 discard unused NS77 24 h RT77 - do NOT use 50 mg/50 mL portion23 aluminum- 100 mg/100mL 100-500 mL† containing needle, (Teva) syringe or tubing77 (RT)(PFL) or 2 L D5-½NS or - suggested dose no preservative77 D5-⅓NS limits relate to the containing 37.5 g physical limitations of mannitol77 of the bag size and added drug volume; it is not a concentration- dependent property of the drug

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 23/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

do NOT use D5W

Cassette: at least 7 days78 qs to 100 mL with bacteriostatic NS only via SIMS DELTEC INC. MEDICATION CASSETTES®78 filter drug and diluent through 0.22 micron filter as each solution is being introduced into the cassette

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 24/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Cytarabine 1000 mg/10mL N/A 100 mg/mL85 discard unused 0.1-37.5 mg/mL 10 d F, 48 h RT85 2000 mg/20mL portion30,85 NS, D5W, SWI85 (Pfizer/Hospira) **(PFL) (RT)(PFL) 100 mL† no preservative85

Cytarabine IT injection N/A 100 mg/mL85 use within 4 h of diluents containing use within 4 h of initial - auxiliary info: IT 1000 mg/10mL initial vial preservatives should vial puncture30 injection30 2000 mg/20mL record time of puncture30 NOT be used for - label to include (Pfizer/Hospira) puncture intrathecal **(PFL) route in full (i.e., (RT)(PFL) administration85 INTRATHECAL no preservative85 injection) attached qs to 6 mL with to both syringe and preservative free outer ziplock bag88 NS86,87

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 25/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Cytarabine 1000 mg/10mL N/A 100 mg/mL89 discard unused 0.1-37.5 mg/mL 10 d F, 48 h RT89 2000 mg/20mL portion30,89 NS, D5W, SWI89 (PMS) **(PFL) (RT)(PFL) 100 mL† no preservative89

Cytarabine IT injection N/A 100 mg/mL89 use within 4 h of diluents containing use within 4 h of initial - auxiliary info: IT 1000 mg/10mL initial vial preservatives should vial puncture30 injection30 2000 mg/20mL record time of puncture30 NOT be used for - label to include (PMS) puncture intrathecal **(PFL) route in full (i.e., (RT)(PFL) administration89 INTRATHECAL no preservative89 injection) attached qs to 6 mL with to both syringe and preservative free outer ziplock bag88 NS86,87

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 26/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Dacarbazine 100 mg 100 mg: 10 mg/mL90 72 h F, 8 h RT90 0.19–3.0 mg/mL 24 h F, 8 h RT90 - protect container 200 mg 9.9 mL SWI90 NS, D5W90 from light during (Abraxis) **(PFL)65,90 storage and (F)(PFL) 200 mg: 500-1000 mL† administration91 no preservative90 19.7 mL SWI90 - overfill unknown

Dacarbazine 200 mg 200 mg: 10 mg/mL92 8 h RT, 48 h F92 0.19-3.0 mg/mL 24 h F92 - protect container 600 mg 19.7 mL SWI92 NS, D5W17,92 from light during (Hospira) (PFL)93 **(PFL)91 storage and (F)(PFL) 600 mg: 500-1000 mL† administration91 no preservative92 59.1 mL SWI92 - no overfill93,94

Dacarbazine 600 mg 59.1 mL SWI95 10 mg/mL95 24 h F, 8 h RT95 0.19-3.0 mg/mL 24 h F95 - protect container (Pfizer) NS, D5W95 from light during (F)(PFL) **(PFL)91 storage and no preservative95 500-1000 mL† administration91

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 27/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Daratumumab 100 mg/5mL N/A 20 mg/mL98 discard unused 500-1000 mL NS 24 h F, followed by 15 - administer with 400 mg/20mL portion98 h infusion (total 39 h)98 0.2 micron in-line (Janssen) dilute to final volume filter98 (F)(PFL) by withdrawing allow bag to come to - discard if visible do not shake volume from bag room temperature, particles are no preservative98 equal to volume of then use immediately98 observed98 drug to be added98 - complete infusion **(PFL) within 15 hours98 mix by gentle inversion98

DAUNOrubicin 20 mg 4 mL SWI99 5 mg/mL99,102 48 h F, 24 h RT101 100-250 mL NS99 48 h F, 24 h RT99 (Erfa Canada Inc.)99 (RT)(PFL)100 no data for D5W101 no preservative101

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 28/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Degarelix 80 mg 80 mg: 20 mg/mL104 2 h RT104 SC syringe104 2 h RT104 120 mg 4.2 mL SWI (Ferring) (supplied diluent)104 (RT) do not shake104 no preservative105 120 mg: 40 mg/mL104 3 mL SWI (supplied diluent)104

swirl gently; avoid shaking to prevent foam formation104

reconstitution may take up to 15 min104

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 29/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Dexrazoxane 250 mg 250 mg: 10 mg/mL108 6 h F, RT108 1.3 – 5.0 mg/mL 6 h F, RT108 500 mg 25 mL NS, D5W108 (Mylan USA)107 sodium lactate (RT) (supplied)108 no preservative108 500 mg: 50 mL sodium lactate (supplied)108

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 30/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Dinutuximab 17.5 mg/5 mL N/A 3.5 mg/mL111 discard unused 100 mL NS111 initiate infusion - do NOT shake111 (Unither/United portion30 within 4 h of dilution; Therapies) mix by gentle refrigerate bag if not (F)(PFL) inversion111 hung immediately111 do not shake no preservative111 complete administration within 24 h of dilution111

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 31/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

14 d F30,113

**(PFL)112

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 32/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

14 d F30,113

**(PFL)112

DOCEtaxel 20 mg/2 mL N/A 10 mg/mL118 14 d F, RT30,119 0.3-0.74 mg/mL complete - use non-DEHP 80 mg/8 mL NS, D5W118 administration within bag and IV 160 mg/16 mL 24 h F, 4 h RT118,120 administration (Sandoz) 100-500 mL† set118 (F,RT)(PFL) preservative118

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 33/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

DOXOrubicin 10 mg/5 mL N/A 2 mg/mL123 8 h123 syringe123 24 h F, RT from initial - for ULYEPOCHR 20 mg/10 mL vial puncture123 protocol, see entry 50 mg/25 mL for EPOCHR 200 mg/100 mL (3-in-1solution (Accord) containing (F)(PFL) etoposide, no preservative123 DOXOrubicin, vinCRIStine)

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 34/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

(NS reconstitution takes longer)124

DOXOrubicin 10 mg/5 mL N/A 2 mg/mL126 8 h126 syringe126 48 h F, 24 h RT126 - for ULYEPOCHR 20 mg/10 mL from initial vial protocol, see entry 50 mg/25 mL record time of puncture for EPOCHR 200 mg/100 mL puncture (3-in-1solution (Teva/Novopharm) containing (F)(PFL) etoposide, no preservative126 DOXOrubicin, vinCRIStine)

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 35/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

DOXOrubicin Pegylated Liposomal N/A 2 mg/mL128 discard unused D5W only128 24 h F128 - do not filter128 20 mg/10 mL portion128 (Janssen) < 90 mg: (F) 250 mL128 no preservative128 ≥ 90 mg: 500mL128

DOXOrubicin Pegylated Liposomal N/A 2 mg/mL129 discard unused D5W only129 24 h F129 - do not filter129 20 mg/10 mL portion129 50 mg/25 mL < 90 mg: (Taro) 250 mL129 (F) no preservative129 ≥ 90 mg: 500mL129

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 36/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Enfortumab vedotin 20 mg 20 mg: 10 mg/mL131 4 h F131 0.3-4 mg/mL 8 h F131 - discard if visible 30 mg 2.3 mL SWI131 NS, D5W, Lactated particles are (Astellas) **(PFL)131 Ringer’s131 **(PFL)131 observed131 (F)(PFL) 30 mg: do not shake 3.3 mL SWI131 mix by gentle no preservative131 inversion131 direct diluent against side of vial during reconstitution131

swirly slowly to dissolve; do not shake131

let sit until bubbles are gone (≥ 1 min) 131

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 37/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Epirubicin 10 mg/5 mL N/A 2 mg/mL133 8 h133 syringe133 48 h F, 24 h RT 50 mg/25 mL from initial vial 200 mg/100 mL record time of puncture133 (Fresenius Kabi) puncture (F)(PFL) no preservative133 100 mL* 48 h F, RT23,133 NS, D5W

Epirubicin 10 mg/5 mL N/A 2 mg/mL134 8 h134 syringe134 48 h F, 24 h RT from 50 mg/25 mL initial vial puncture134 200 mg/100 mL record time of (Pfizer) puncture (F)(PFL) 100 mL* 48 h F, RT135 no preservative134 NS, D5W65

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 38/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability (for IV bag size selection, Precautions/Notes Manufacturer, Preservative see Notes†) Status) EPOCHR (ULYEPOCHR protocol) see brand specific see brand specific see brand etoposide dose etoposide - final product is a (RT) entries for: entries for: specific entries ≤125 mg/24 h: concentration 3-in-1 solution no preservative23,136-139 DOXOrubicin as DOXOrubicin, for: DOXOrubicin, in 500 mL NS ≤0.25 mg/mL: containing applicable etoposide, etoposide, complete etoposide, vinCRIStine vinCRIStine etoposide dose administration within DOXOrubicin, >125 mg/24 h: 72 h RT vinCRIStine (refer in 1000 mL NS to ULYEPOCHR precipitation occurs at protocol) etoposide - use non-DEHP concentrations bag and tubing >0.25 mg/mL only - administer with 0.2 micron in-line filter

eriBULin 1 mg/2 mL N/A 0.5 mg/mL140 discard unused IV syringe140 24 h F, 6 h RT140 - do not administer (Eisai Limited) portion23,140 through dextrose (RT)(PFL)140 containing lines140 no preservative23 - vials contain dehydrated alcohol USP (5% v/v)140

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 39/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 40/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability (for IV bag size selection, Precautions/Notes Manufacturer, Preservative see Notes†) Status) Etoposide 100 mg/5 mL N/A 20 mg/mL143 discard unused 0.2-0.4 mg/mL 0.2-0.3 mg/mL: - use non-DEHP 200 mg/10 mL portion143 NS143 7 d F,144 2 d RT144,145 bag and tubing 500 mg/25 mL only 1000 mg/50 mL 100-1000 mL† 0.4-0.5 mg/mL: - administer with (Teva/Novopharm) 1 d F,144 1d RT144 0.2 micron in-line (RT)(PFL) filter142 no preservative143 0.6-9.0 mg/mL: - for ULYEPOCHR generally unstable protocol, see entry for EPOCHR 9.5 mg/mL: (3-in-1solution 2 d F,144 1d RT144 containing etoposide, 10-12 mg/mL: DOXOrubicin, 7 d F,144 2 d RT144,145 vinCRIStine)

Stability is concentration dependent

D5W143 4 h RT143,146

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 41/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Filgrastim (NEUPOGEN®) N/A 300 mcg/mL151 discard unused SC syringe151 14 d F23,152 - albumin is added 300 mcg/1 mL portion23 to D5W to prevent 480 mcg/1.6 mL filgrastim (Amgen) 50-100 mL 7 d F, 48 h RT23,152 adsorption to (F)(PFL) D5W only153 plastic151 do not shake - incompatible with no preservative151 in PVC, polyolefin, or saline151,153 glass151 - do NOT dilute to less than 5 (for filgrastim mcg/mL151 concentrations of 5-15 mcg/mL in D5W, add albumin 2 mg/mL)151

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 42/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Fludarabine 50 mg N/A 25 mg/mL156 discard unused dilute to maximum of 48 h F, 24 h RT156 (Teva/Novopharm) portion156 1 mg/mL (F) NS, D5W156 no preservative156 100 mL†

Fluorouracil 5000 mg/100 mL N/A 50 mg/mL157 48 h RT23,158 syringe157 48 h RT23,158 (Accord) (RT)(PFL) no preservative157 0.5-10 mg/mL D5W158 48 h RT23,158

500 mL†

CIVI: ambulatory complete within pump159 8 d158

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 43/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

500 mL†

CIVI: ambulatory complete within pump159 8 d17,65,162,163

Fluorouracil 500 mg/10 mL N/A 50 mg/mL164 48 h RT30,165 syringe 48 h RT30,164 5000 mg/100 mL (Sandoz) (RT)(PFL) 0.35-15 mg/mL 48 h RT30,165 no preservative164 D5W165

500 mL†

CIVI: ambulatory complete within pump159 8 d17,65,162,163

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 44/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Gemcitabine intravesical 1000 mg: 38 mg/mL166 24 h RT166 syringe up to 38 mg/mL166: 1000 mg 25 mL NS166 24 h RT 2000 mg refrigeration may dilute with NS to final (Accord) 2000 mg: cause volume of 45-90 (RT) 50 mL NS166 crystallization166 mL116,117,169,170 no preservative166

Gemcitabine 200 mg/5.3 mL N/A 38 mg/mL171 discard unused syringe171 24 h RT171 1000 mg/26.3 mL portion171 2000 mg/52.6 mL (Pfizer/Hospira) 0.1–38 mg/mL (F) NS, D5W171 no preservative171 250 mL†

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 45/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Gemcitabine (NOTE: concentration) N/A 40 mg/mL172 discard unused syringe172 24 h RT172 CAUTION: 200 mg/5 mL portion172 alternative 1000 mg/25 mL concentration 2000 mg/50 mL 0.1–40 mg/mL (Sandoz) NS, D5W172 (F) 172 no preservative 250 mL†

Gemcitabine (NOTE: concentration) N/A 40 mg/mL172 discard unused syringe up to 40 mg/mL172: CAUTION: intravesical portion172 24 h RT alternative 200 mg/5 mL dilute with NS to final concentration 1000 mg/25 mL volume of 45-90 2000 mg/50 mL mL116,117,169,170 (Sandoz) (F) no preservative172

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 46/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability (for IV bag size selection, Precautions/Notes Manufacturer, Preservative see Notes†) Status) Gemtuzumab ozogamicin 5 mL SWI173 1 mg/mL173 6 h F, 0.075 – 0.234 mg/mL complete - administer with 4.5 mg 3 h RT173 NS173 administration within 0.2 micron in-line (Pfizer) allow vial to come to 12 h F, 6 h RT173 filter173 (F)(PFL) room temperature protect from light 25 mL† - protect infusion no preservative173 prior to use (~5 if not used (PFL)** bag from light min)173 immediately173 mix by gentle (including UV) inversion; if refrigerated, bring during swirl gently to mix; do NOT shake173 bag to RT over 1 h administration173 do NOT shake173 prior to - protect administration173 administration line from light ONLY if hang time will be longer than 2 h173,174 - solution may contain white particulates which do not affect product quality173

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 47/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

vial contents under negative pressure175

do NOT use BWI to reconstitute175

IDArubicin PFS 5 mg/5 mL N/A 1 mg/mL175 48 h F, 24 h RT syringe175 4 h - avoid alkaline 10 mg/10 mL from initial puncture23 solutions175 20 mg/20 mL **(PFL)175 (Pfizer) (F)(PFL) no preservative175

IDArubicin 5 mg/5 mL N/A 1 mg/mL176 discard unused syringe176 4 h - avoid alkaline 10 mg/10 mL solution176 from initial puncture23 solutions176 20 mg/20 mL (Fresenius Kabi) (F)(PFL) no preservative176

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 48/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

shake well

Ifosfamide 1000 mg 1000 mg: 50 mg/mL178 48 h F, 24 h 0.6-20 mg/mL 72 h F, 24 h RT178 3000 mg 20 mL SWI178 RT23,178 NS, D5W, Lactated (Fresenius Kabi) Ringer’s178 24 h F, RT when mixed 65 (RT) 3000 mg: with mesna no preservative178 60 mL SWI178 500 mL†

shake well

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 49/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

(or may also use empty IV bag and qs to final volume of 250 mL with NS, D5W179)

Inotuzumab ozogamicin 4 mL SWI180 0.25 mg/mL180 4 h F180 0.01-0.1 mg/mL NS180 complete - do NOT shake180 0.9 mg administration within - protect container (Pfizer) gently swirl vial to record time of dilute dose within 25-50 mL† 8 h of reconstitution from UV and (F)(PFL) mix180 reconstitution 4 hours of F, RT180 fluorescent light no preservative180 reconstitution180 mix by gentle during storage and inversion180 (PFL)180 administration180,181 protect from light - protect if not used if refrigerated, bring administration line immediately181 bag to RT over 1 h from light ONLY if prior to hang time will be administration180 longer than 1 h180,181

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 50/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

50 mL* NS182

Interferon Alfa -2b 10 million units 1 mL supplied 10 million 24 h F182 syringe182 24 h F23,183 - after (Merck) diluent (SWI)182 units/mL182 reconstitution, (F) provides an no preservative (unless do NOT shake; isotonic solution reconstituted with roll to reconstitute182 final concentration 24 h F, RT183 which may be used BWI)182 ≥ 0.1 million IU/mL182 for intralesional injection182 100 mL* NS182 - non-reconstituted vials can be kept at RT for up to 4 1 mL BWI182 14 d F23,182 syringe182 14 d F23,182 weeks before use; discard if not do NOT shake; reconstituted for roll to reconstitute182 final concentration 24 h F, RT183 use within this 182 ≥ 0.1 million IU/mL182 time

100 mL* NS182

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 51/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability (for IV bag size selection, Precautions/Notes Manufacturer, Preservative see Notes†) Status) Ipilimumab 50 mg/10 mL N/A 5 mg/mL184 24 h F, RT184 1-4 mg/mL 24 h F, RT184 - do NOT shake184 200 mg/40 mL NS, D5W184 - administer with (BMS Canada) 0.2 or 0.22 in-line (F)(PFL) 25-250 mL† filter184 no preservative184 - vials may contain OR translucent-to- undiluted in empty white amorphous viaflex bag or glass particles184 bottle - discard if cloudy or has pronounced (allow vials to stand at colour change RT for ~5 min prior to (should be clear to withdrawal of pale yellow)184 contents)184

Irinotecan 40 mg/2 mL N/A 20 mg/mL185 discard unused 0.12-3 mg/mL 48 h F, 24 h RT 100 mg/5 mL portion185 D5W (preferred), 500 mg/25 mL NS185 **(PFL)185 (Accord) (RT)(PFL) 250-500 mL† no preservative185

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 52/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Irinotecan Liposome 43 mg/10 mL N/A 4.3 mg/mL188 discard unused to a final volume of 24 h F, 4 h RT188 - do not use in-line (Servier) portion188 500 mL NS, D5W188 filter188 (F)(PFL) **(PFL) - expressed as no preservative188 mix by gentle irinotecan free inversion188 (allow product to come base to RT prior to administration if stored in F)188

Isatuximab 100 mg/5 mL N/A 20 mg/mL189 discard unused 250 mL 48 h F - administer with a 500 mg/25 mL portion189 NS, D5W189 plus an additional 0.2 micron in-line (sanofi-aventis) inspect vial and 8 h RT including filter189,190 (F)(PFL) discard if mix by gentle infusion time189,190 do not shake discolouration or inversion; do NOT no preservative189 visible particles are shake189,190 present189,190

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 53/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

* Suggested volume based on usual dose range and any concentration range of stability data † see BC Cancer IV Bag Selection table: standardized bag sizes are provided for select Benefit Drugs with concentration-dependent stability or large drug volume ** Protect from light means minimizing exposure to direct sunlight over a storage period. More specific information on protection from light (eg, protecting container and tubing during administration) will be indicated in the Special Precautions/Notes column. *** Contains DMA (N,N dimethylacetamide). Product may be incompatible with closed system transfer devices such as ChemoLock.

Centres are not to change content locally. All suggestions for change are to be forwarded to the Cancer Drug Manual editor.

Explanatory Notes:

Stability data assumes products prepared using standard aseptic technique in biological safety cabinet at low risk for contamination according to the classification outlined in USP 797.192,193 Vial stability: Stability of solution after first puncture or reconstituted solution. Storage temperature: If information states same stability with refrigerator and room temperature storage, then fridge stability is bolded as preferred (ie, to minimize growth of micro-organisms). Discard unused portion: Unused portion from single use vials should be discarded at the end of the day. “overfill known” is stated if the manufacturer states overfill that is present is within acceptable limits. “Complete administration within __” is stated if the manufacturer specifies that the infusion must be completed in a specific time frame following preparation, usually including entire time required for preparation (from first puncture), storage, and administration of infusion. Nomenclature for In-line filters has been standardized in the chart to 0.2 micron filter size. For more information, refer to CDM drug monograph.

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 54/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

Abbreviations:

BWI = bacteriostatic water for injection CIVI: ambulatory pump = Continuous Intravenous Infusion (e.g., elastomeric infusor) D5W = dextrose 5% in water DMA = N,N dimethylacetamide F = refrigerate Non-DEHP = not containing Di(2-ethylhexyl) phthalate (DEHP) NS = normal saline PFL = protect from light RT = room temperature SWI = sterile water for injection

References:

1. Agensys. Pharmacy Guide Protocol AGS-16C3F-15-3: A multi-center, open label, randomized phase 2 study of AGS-16C3F vs. axitinib in metastatic renal cell carcinoma. Santa Monica, California; 8 June 2016 - version 2.0. 2. BC Cancer. (Study Code GUT16C3F) Clinical Trial Dispensing Instructions for: A multi-center, open label, randomized phase 2 study of AGS-16C3F vs. aXitinib in metastatic renal cell carcinoma. Vancouver, British Columbia: BC Cancer; 18 April 2018. 3. Laura Standley. Lead Clinical Study Manager, Astellas Pharma Global Development Inc. Personal communication. 23 January 2019. 4. SteriMax Inc. PROLEUKIN® product monograph. Oakville, Ontario; 6 July 2020. 5. McEvoy GK, editor. AHFS 2008 Drug Information. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc. p. 917-925. 6. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011;365(22):2055-2066. 7. Koreth J, Alyea EP, Cutler C, Ho VT, et al. Clinical Study Protocol: A phase I study of ultra-low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease. Boston, MA, USA: Dana Farber Cancer Institute; Harvard Medical Centre; 14 Dec 2010. 8. Temple-Oberle CF, Byers BA, Hurdle V, et al. Intra-lesional interleukin-2 for in-transit melanoma. J Surg Oncol 2014;109(4):327-331. 9. BC Cancer Skin and Melanoma Tumour Group. (SMILALD) BC Cancer Protocol Summary for Treatment of In-Transit Melanoma Using Intralesional Aldesleukin (IL-2). Vancouver, British Columbia: BC Cancer; 1 June 2021. 10. BC Cancer Skin and Melanoma Tumour Group. (SMILALD) BC Cancer Protocol Summary for Treatment of In-Transit Melanoma Using Intralesional Aldesleukin (IL-2). Vancouver, British Columbia: BC Cancer; 1 August 2021. 11. Rui Paiva. Business Unit Director, Transplant and Oncology. Personal communication. 1 June 2009. 12. Bayer HealthCare Pharmaceuticals. MabCampath® Package Insert. Toronto, Ontario; 1 September 2007. 13. Lundin J, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 22 January 2004(18):484-490. 14. Berlex Canada Inc. Campath Drug Information. San Antonio, Texas; undated. 15. Janssen Biotech Inc. RYBREVANT® full prescribing information. Horsham, PA, USA; May 2021. 16. Erfa Canada Inc. AMSA PD® injection product monograph. Westmount, Quebec; 16 August 2005. 17. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 6 January 2006. 18. Tanya Leduc. Pharmacist. Acting editor, BC Cancer Agency Cancer Drug Manual. Personal communication. 2 June 2008. 19. Teva Canada Limited. TRISENOX® product monograph. Toronto, Ontario; 16 October 2020. 20. CGF Pharmatec for Jazz Pharmaceuticals France SAS. ERWINASE® product monograph. Montreal, Quebec; 30 August 2016.

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 55/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

21. Hoffmann-La Roche Limited. TECENTRIQ® product monograph. Mississauga, Ontario; 19 September 2019. 22. EMD Serono. BAVENCIO® product monograph. Mississauga, Ontario; 4 May 2018. 23. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 September 2007. 24. Celgene Inc. VIDAZA® product monograph. Mississauga, Ontario; 17 May 2012. 25. Kevin Mejo. Medical Information, Celgene Inc. Personal communication. 21 June 2017. 26. Tutino A, Lai M. Cold water reconstitution of Vidaza with subsequent refrigerated storage prolongs drug stability. Eur J Oncol Pharm 2011;5(3-4):24, 25, 34. 27. Celgene Corporation. VIDAZA® full prescribing information. Summit, NJ, USA; December 2012. 28. Dr. Reddy's Laboratories Limited. Azacitidine for injection product monograph. Mississauga, Ontario; 19 April 2017. 29. Merck Canada Inc. OncoTICE® product monograph. Kirkland, Quebec; 29 April 2019. 30. BC Cancer. Provincial Pharmacy Directive Number II-20: Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer; 5 December 2018. 31. Merck & Co. Inc. TICE® BCG full prescribing information. Whitehouse Station, New Jersey, USA; March 2019. 32. Repchinsky C editor. ImmuCyst monograph, Compendium of Pharmaceuticals and Specialties. Ottawa, Ontario; 2005. 33. GlaxoSmithKline. Belantamab mafodotin (GSK2857916) Investigational Product Information for Compassionate Use - Version 5.0. Collegeville, Pennsylvania, USA; 25 September 2019. 34. GlaxoSmithKline. Belantamab mafodotin (GSK2857916) LYOPHILIZED POWDER Investigational Product Information for Compassionate Use - Version 1. Collegeville, Pennsylvania, USA; 26 October 2020. 35. GlaxoSmithKline. BLENREP® full prescribing information. Research Triangle Park, North Carolina, USA; August 2020. 36. Spectrum Pharmaceuticals Inc. BELEODAQ® full prescribing information. Irvine, CA, USA; April 2012. 37. Teva Canada Limited. TREANDA® product monograph. Toronto, Ontario; 10 January 2018. 38. Lundbeck Canada Inc. TREANDA® product monograph. Montreal, Quebec; 22 August 2012. 39. Hoffman-La Roche Limited. AVASTIN® product monograph. Mississauga, Ontario; 6 June 2018. 40. Amgen Canada Inc. MVASI® product monograph. Mississauga, Ontario; 5 June 2019. 41. Pfizer Canada ULC. ZIRABEV® product monograph. Kirkland, Quebec; 14 June 2019. 42. Fresenius Kabi Canada Ltd. Bleomycin for injection product monograph. Richmond Hill, Ontario; 1 June 2016. 43. Pfizer Canada Inc. Bleomycin for Injection product monograph. Kirkland, Quebec; 8 August 2017. 44. Amgen Canada Inc. BLINCYTO® product monograph. Mississauga, Ontario; 12 July 2016. 45. Actavis Pharma Company. ACT BORTEZOMIB® Bortezomib for injection product monograph. Mississauga, Ontario; 24 September 2015. 46. Law S, Charbonneau LF, Iazzeta J, et al. Stability of generic formulations of bortezomib 1.0 and 2.5 mg/mL in vials and syringes stored at 4°C and room temperature (23°C). CJHP Canadian Society of Hospital Pharmacists Professional Practice Conference 2018 Poster Abstracts.Feb 4 - 6, 2018. 47. BC Cancer. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer; 19 September 2007. 48. Apotex Inc. Bortezomib for injection product monograph. Toronto, Ontario; 15 February 2019. 49. Walker SE, Law S, Ma N. (Abstract) Stability of 1.0 and 2.5 mg/mL bortezomib solution in vials and syringes following reconstitution with 0.9% sodium chloride at 4ºC and room temperature (25ºC). (Apotex brand).Department of Pharmacy, Sunnybrook Health Sciences Centre and Leslie Dan Faculty of Pharmacy, University of Toronto. Toronto, ON 2019 . 50. Janssen Inc. VELCADE® product monograph. Toronto, Ontario; 20 June 2013. 51. Juno Pharmaceuticals Corp. Bortezomib for injection product monograph. Mississauga, Ontario; 23 Jun 2020. 52. Law S, Charbonneau F, Iazzeta J, et al. Stability of generic formulations of bortezomib 1.0 and 2.5 mg/mL in vials and syringes stored at 4°C and room temperature (23°C or 25°C). CJHP 2021;74(1):57-69. 53. Teva Canada Limited. Bortezomib for injection® product monograph. Toronto, Ontario; 22 January 2015. 54. GMD Distribution Inc. for Seattle Genetics Inc. ADCETRIS® product monograph. Oakville, Ontario; 1 February 2013. 55. Pharmascience Inc. Busulfan for injection product monograph. Montreal, Quebec; 14 June 2018. 56. SteriMax Inc. Busulfan for injection product monograph. Oakville, Ontario; 4 May 2017. 57. Sandoz Canada Inc. Cabazitaxel for injection product monograph. Boucherville, Quebec; 17 December 2019. 58. sanofi-aventis Canada Inc. JEVTANA® product monograph. Laval, Quebec; 7 September 2017. 59. Accord Healthcare Inc. Carboplatin injection® product monograph. Kirkland, Quebec; 15 May 2019.

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 56/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

60. Omega Laboratories Ltd. Carboplatin injection product monograph. Montreal, Quebec; 24 March 2011. 61. Nayla El Zir. Associate, Regulatory Affairs, Omega Laboratories Limited. Personal communication. 12 April 2017. 62. Pfizer Canada ULC. Carboplatin injection product monograph. Kirkland, Quebec; 31 December 2018. 63. Novopharm Limited. Carboplatin Package Insert. Toronto, Canada; Undated. 64. Manjinder S Kang. Regulatory Affairs Drug Information Pharmacist, Novopharm Canada. Personal communication. 14 March 2005. 65. Trissel LA. Handbook on Injectable Drugs. 13th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2005. 66. Repchinsky C editor. Paraplatin-AQ, Compendium of Pharmaceuticals and Specialties. 12th ed. Ottawa, Ontario: Canadian Pharmacists Association; 2004. 67. Amgen Canada Inc. KYPROLIS® product monograph. Mississauga, Ontario; 6 July 2017. 68. Luis Simao. Area Manager, ICU Medical Canada. Personal communication. 11 May 2018. 69. Diane Lord. Medical Information, Amgen Canada Inc. Personal communication. 8 May 2018. 70. Bristol Laboratories of Canada. BiCNU Package Insert. Montreal, Canada; 2002. 71. sanofi-aventis Canada Inc. LIBTAYO® product monograph. Laval, Quebec; 10 April 2019. 72. ImClone LLC (distributed by Eli Lilly Canada Inc). ERBITUX® product monograph. Toronto, Ontario; 10 January 2018. 73. Accord Healthcare Inc. Cisplatin injection product monograph. Kirkland, Quebec; 15 February 2019. 74. Pfizer Canada ULC. Cisplatin injection product monograph. Kirkland, Quebec; 7 December 2018. 75. Sandoz Canada Inc. Cisplatin Injection BP product monograph. Boucherville, Quebec; 13 April 2011. 76. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 September 2007. 77. Teva Canada Limited. Cisplatin injection® product monograph. Toronto, Ontario; 6 March 2013. 78. Pharmaceutical Partners of Canada, Inc. Cladribine For Injection product monograph. Richmond Hill, Ontario; 27 November 2008. 79. BC Cancer Agency Lymphoma Tumour Group. (LYCDA) BCCA Protocol Summary for Treatment of Hairy Cell Leukemia with Cladribine. Vancouver, British Columbia: BC Cancer Agency; 1 February 2007. 80. de Lemos ML, Hamata L. Stability issues of parenteral chemotherapy drugs. J Oncol Pharm Pract Mar 2007;13(1):27-31. 81. Baxter Corporation. PROCYTOX® product monograph. Mississauga, Ontario; 7 September 2012. 82. Baxter Corporation Medical Information. Personal communication. 14 May 2020. 83. Baxter Healthcare Corporation. Cyclophosphamide for injection full prescribing information. Deerfield, Illinois USA; May 2013. 84. Trissel's® 2 Clinical Pharmaceutics Database - Lexicomp Online (database on the Internet). Cyclophosphamide. Wolters Kluwer Clinical Drug Information Inc., undated. Available at: http://online.lexi.com. Accessed 14 May 2020. 85. Pfizer Canada Inc. Cytarabine Solution for Injection product monograph. Kirkland, Quebec; 3 November 2015. 86. BC Cancer Lymphoma Tumour Group. (LYIT) BC Cancer Protocol Summary for Treatment of Lymphoma using Intrathecal Methotrexate and Cytarabine. Vancouver, British Columbia: BC Cancer; 1 June 2014. 87. BC Cancer Miscellaneous Origin Tumour Group. (MOIT) BC Cancer Protocol Summary for Solid Tumours using Intrathecal Methotrexate and/or Thiotepa and/or Cytarabine. Vancouver, British Columbia: BC Cancer; 1 October 2018. 88. BC Cancer. Systemic Therapy Policy and Procedure III-50: Administration of High Alert Medications by the Intrathecal Route via Lumbar Puncture or Ommaya Reservoir. Vancouver, British Columbia; 1 May 2019. 89. Pharmascience Inc. Cytarabine Solution for Injection product monograph. Montreal, Quebec; 14 February 2017. 90. Abraxis Pharmaceutical Products. Dacarbazine product information package. Schaumburh, IL; December 2006. 91. Trissel L. Handbook on injectable drugs. 13th ed. Bethesda, Maryland: American Society of Health-System Pharmacists; 2005. p. 428-431. 92. Mayne Pharma (Canada) Inc. DACARBAZINE FOR INJECTION product monograph. Montreal, Quebec; 25 July 2003. 93. John Korontzis. Regulatory Affairs Associate,Mayne Pharma Canada. Personal communication: Dacarbazine. 8 February 2005. 94. Caunce, Robert. Quality System Manager, Hospira Australia. Personal communication. 12 March 2008. 95. Pfizer Canada Inc. Dacarbazine for Injection product monograph. Kirkland, Quebec; 31 May 2018. 96. Recordati Rare Diseases Inc. COSMEGEN® product monograph. Lebanon, New Jersey USA; 24 July 2014. 97. Andy Harbrow.Global Medical Services Manager, Primevigilance (for Recordati Rare Diseases Inc.). Personal communication: dactinomycin solutions for infusion. 15 July 2014. 98. Janssen Inc. DARZALEX® product monograph. Toronto, Ontario; 29 June 2016. 99. Erfa Canada Inc. Daunorubicin injection product monograph. Westmount, Quebec; 6 December 2002.

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 57/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

100. Erfa Canada Inc. Daunorubicin Material Safety Data Sheet. Montreal, Quebec; 3 October 2007. 101. Henri Knafo MD. Medical Director, Erfa Canada Inc. Personal communication. 14 July 2008. 102. Henri Knafo MD.Medical Director, Erfa Canada Inc. Personal communication. 09 July 2008. 103. Novopharm Limited. Daunorubicin Package Insert. Toronto, Canada; Undated. 104. Ferring Pharmaceuticals. FIRMAGON® product monograph. North York, Ontario; 20 March 2013. 105. Ferring Pharmaceuticals. FIRMAGON® product monograph. North York, Ontario; 06 November 2009. 106. Amgen Canada Inc. XGEVA® product monograph. Mississauga, Ontario; 14 October 2011. 107. Health Canada. Recalls and safety alerts - Importation of US-labelled dexrazoxane for injection distributed by Mylan Pharmaceuticals ULC due to shortage of Canadian-labelled dextrazoxane. 1 December 2020. Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html. Accessed 2 December 2020. 108. Mylan Institutional LLC. Dexrazoxane hydrochloride product monograph. Rockford, Illinois USA; April 2018. 109. Pfizer Canada Inc. ZINECARD® product monograph. Kirkland, Quebec; 12 August 2010. 110. Pfizer Canada Inc. ZINECARD® product monograph. Kirkland, Quebec; 30 March 2015. 111. Unither Biotec Inc. for United Therapeutics Corp. UNITUXIN® product monograph. Magog, Quebec; 28 November 2018. 112. Pfizer Canada ULC. Docetaxel injection product monograph. Kirkland, Quebec; 26 March 2021. 113. Hospira Canada Clinical Support Team, Hospira Canada Healthcare Corporation. Personal communication. 21 March 2011. 114. Josee Lloyd. Senior Clinical Specialist, Hospira Clinical Support Team, Hospira Healthcare Corporation. Personal communication: multidose vials and venting needles. 13 July 2011. 115. Pfizer Canada Inc. Docetaxel injection product monograph. Kirkland, Quebec; 1 June 2018. 116. Steinberg RL, Thomas LJ, Brooks N, et al. Multi-institution evaluation of sequential intravesical gemcitabine and docetaxel as rescue therapy for non-muscle invasive bladder cancer. J Urol May 2020;203(5):902-909. 117. BC Cancer Genitourinary Tumour Group. (GUBGEMDOC) BC Cancer Protocol Summary for Intravesical Therapy for Non-Muscle Invasive Bladder Cancer Using Gemcitabine and Docetaxel. Vancouver, British Columbia: BC Cancer; 1 August 2021. 118. Sandoz Canada Inc. Docetaxel injection product monograph. Boucherville, Quebec; 17 November 2020. 119. Bazundama Bazuta Feza Sandrine. Medical Information Intern, Sandoz Canada Inc. Personal communication: in-house vial stability for docetaxel injection. 14 August 2018. 120. Bazundama Bazuta Feza Sandrine. Medical Information Intern, Sandoz Canada Inc. Personal communication: in-house product stability of diluted docetaxel injection. 14 August 2018. 121. Vigneron J, Astier A, Trittler R, et al. SFPO and ESOP recommendations for the practical stability of anticancer drugs: an update. Ann Pharm Fr 2013;71(6):376-389. 122. Trissel's® 2 Clinical Pharmaceutics Database - Lexicomp Online (database on the Internet). Docetaxel. Wolters Kluwer Clinical Drug Information Inc., undated. Available at: http://online.lexi.com. Accessed 7 July 2021. 123. Accord Healthcare Inc. Doxorubicin injection® product monograph. Montreal, Quebec; 9 April 2014. 124. Mayne Pharma (Canada) Inc. Doxorubicin Package Insert. Montreal, QC; Undated. 125. Mayne Pharma (Canada) Inc. Doxorubicin Product Monograph. Montreal, Quebec; 2002. 126. Novopharm Limited. Doxorubicin Product Monograph. Scarborough, Ontario; 8 November 1996. 127. Pfizer Canada Inc. ADRIAMYCIN® injection product monograph. Kirkland, Quebec; 28 August 2007. 128. Janssen Inc. CAELYX® product monograph. Toronto, Ontario; 10 October 2013. 129. Taro Pharmaceuticals Inc. Taro-DOXOrubicin Liposomal product monograph. Brampton, Ontario; 7 October 2019. 130. AstraZeneca Canada Inc. IMFINZI® product monograph. Mississauga, Ontario; 4 July 2019. 131. Astellas Pharma US Inc. PADCEV® full prescribing information. Northbrook, Illinois, USA; March 2021. 132. Novopharm. Epirubicin for Injection product monograph. Toronto, Ontario; 16 March 2009. 133. Pharmaceutical Partners of Canada, Inc. Epirubicin Hydrochloride Injection product monograph. Richmond Hill, Ontario; 6 July 2010. 134. Pharmacia Canada Inc. Pharmorubicin PFS Package Insert. Mississauga, Ontario; May 2003. 135. Trissel LA. Handbook on Injectable Drugs. 12th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2003. 136. BC Cancer Agency Lymphoma Tumour Group. (ULYEPOCHR) Interim BCCA Protocol Summary for Treatment of Lymphoma with Dose-Adjusted Etoposide, DOXOrubicin, VinCRIStine, Cyclophosphamide, PredniSONE, and riTUXimab (LYEPOCHR) with Intrathecal Methotrexate. Vancouver, British Columbia: BC Cancer Agency; 1 July 2015. 137. Barry Goldspiel. NIH Clinical Centre. Personal communication: EPOCHR. 14 April 2015.

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 58/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

138. Wolfe JL, Thoma LA, Du C, et al. Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection. Am J Health-Syst Pharm 1999;56:985-989. 139. Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med 2013;369:1915-1925. 140. Eisai Limited. HALAVEN® product monograph. Mississauga, Ontario; 17 January 2013. 141. Sandoz Canada Inc. Etoposide injection product monograph. Kirkland, Quebec; 27 February 2012. 142. BC Cancer Agency. Provincial Pharmacy Directive III-50-04: Management of Particulate During Sterile Preparation. Vancouver, British Columbia: BC Cancer Agency; 9 July 2014. 143. Novopharm Limited. Etoposide Product Monograph. Toronto, Ontario; 2000. 144. Lepage R, Walker S, Godin J. Stability and compatibility of etoposide in normal saline. Canadian Journal of Hospital Pharmacy December 2000;53(5):338-345. 145. The United States Pharmacopeial Convention, Inc. General Chapter 797: Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: The United States Pharmacopeial Convention, Inc.; 2003. 146. Angie Chan. Drug Information Pharmacist, Novopharm. Personal communication. 29 September 2006. 147. Bristol-Myers Squibb Company. ETOPOPHOS® product monograph. Princeton, New Jersey, USA; March 2011. 148. Joseph Atallah. Interim County Medical Director. Bristol-Myers Squibb Canada. Personal communication re: new Canadian distributor for ETOPOPHOS®. 15 November 2019. 149. George Gafrey. VP Business Development. Xediton Pharmaceuticals Inc. Personal communication re: new Canadian distributor for ETOPOPHOS®. 27 November 2019. 150. Bristol-Myers Squibb Company. ETOPOPHOS® product monograph. Princeton, New Jersey, USA; September 2013. 151. Amgen Canada Inc. NEUPOGEN® product monograph. MIssissauga, Ontario; 21 March 2014. 152. Amgen Medical Information. Amgen Canada Inc. Personal communication. 8 July 2014. 153. Trissel LA. Handbook on Injectable Drugs. 13th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc; 2005. p. 648-655. 154. Berlex Canada Inc. Fludara Package Insert. Lachine, Quebec; December 1998. 155. Trissel's™2 Clinical Pharmaceutics Database (Parenteral Compatibility) [database on the internet]. Fludarabine. Thomson MICROMEDEX®, Available at: http://www.micromedex.com/. Accessed 14 September, 2007. 156. Novopharm Limited. Fludarabine product information package. Toronto, Ontario; 21 June 2007. 157. Accord Healthcare Inc. Fluorouracil injection® product monograph. Kirkland, Quebec; 30 September 2013. 158. Charles Vachon. Quality and Regulatory Affairs, Accord Healthcare Inc. Personal communication. 29 September 2016. 159. John Korontzis. Regulatory Affairs Associate,Mayne Pharma Canada. Personal communication: Fluorouracil. February 16, 2005. 160. Pfizer Canada Inc. Fluorouracil injection product monograph. Kirkland, Quebec; 17 April 2018. 161. Trissel LA. Fluorouracil. Handbook on Injectable Drugs: 13th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc; 2005. p. 672-681. 162. Stiles ML, Allen Jr LV, Tu YH. Stability of fluorouracil administered through four portable infusion pumps. American Journal of Hospital Pharmacy 1989;46(10):2036-2040. 163. BC Cancer Agency Experimental Therapeutics. Physicochemical stability analysis of fluorouracil products in final chemotherapeutic preparations.Vancouver, BC. 19 August 2011;Study number 50009:1-43. 164. Sandoz Canada Inc. Fluorouracil Injection product monograph. Boucherville, Quebec; 3 April 2012. 165. Alexandre Dussault. Drug Information & Pharmacovigilance Coordinator, Sandoz Canada Inc. Personal communication. 19 November 2015. 166. Accord Healthcare Inc. Gemcitabine injection product monograph. Kirkland, Quebec; 24 March 2020. 167. Astron Research LTD. UK. Gemcitabine for Injection (STBRG/ACGEM/01) Stability Study Report (Dilution Study) 2001. 168. Purvi Agrawal BScPharm. Regulatory Affairs Manager, Accord Healthcare Inc. Personal communication. 07 September 2012. 169. Skinner EC, Goldman B, Sakr WA, et al. SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical Bacillus Calmette-Guerin. J Urol 2013;190(4):1200-1204. 170. BC Cancer Genitourinary Tumour Group. (GUBGEM) BC Cancer Protocol Summary for Intravesical Therapy for Non-Muscle Invasive Bladder Cancer Using Gemcitabine. Vancouver, British Columbia: BC Cancer; 1 November 2019. 171. Pfizer Canada Inc. Gemcitabine Injection (ready to use solution) product monograph. Kirkland, Quebec; 25 October 2018. 172. Sandoz Canada Inc. Gemcitabine hydrochloride solution for injection product monograph. Boucherville, Quebec; 14 August 2014. 173. Pfizer Canada ULC. MYLOTARG® product monograph. Kirkland, Quebec; 28 November 2019. 174. Sharon Keane. Pfizer Canada Medical Information. Personal communication. 7July 2020. 175. Pfizer Canada Inc. IDAMYCIN® product monograph. Kirkland, Quebec; 19 February 2009. 176. Pharmaceutical Partners of Canada, Inc. IDARUBICIN HYDROCHLORIDE INJECTION® product monograph. Richmond Hill, Ontario; 12 November 2009.

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 59/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021

177. Baxter Corporation. IFEX® product monograph. Mississauga, Ontario; 5 April 2012. 178. Pharmaceutical Partners of Canada, Inc. Ifosfamide for Injection product monograph. Richmond Hill, Ontario; 17 January 2008. 179. sanofi-aventis Canada. Iniparib (BSI-201;SAR240550) Special Access Program Guidance for the Physician. Laval, Quebec; 15December2010. 180. Pfizer Canada Inc. BESPONSA® product monograph. Kirkland, Quebec; 15 March 2018. 181. Pfizer Medical Information. Pfizer Canada Inc. Personal communication. 26 November 2018. 182. Merck Canada Inc. INTRON A® product monograph. Kirkland, Quebec; 13 March 2015. 183. Edward Kavalec BSc(Pharm). Medical Services Specialist. Merck Canada Inc. Medical Information. Personal communication. 1 April 2015. 184. Bristol Myers Squibb Canada. YERVOY® product monograph. Montreal, Quebec; 1 February 2012. 185. Accord Healthcare Inc. Irinotecan injection® product monograph. Kirkland, Quebec; 6 May 2014. 186. Pfizer Canada Inc. Irinotecan hydrochloride trihydrate for injection product monograph. Kirkland, Quebec; 6 March 2019. 187. Pfizer Canada Inc. Irinotecan hydrochloride injection product monograph. Kirkland, Quebec; 8 March 2019. 188. Servier Canada Inc. ONIVYDE® product monograph. Laval, Quebec; 4 January 2019. 189. sanofi-aventis Canada Inc. SARCLISA® product monograph. Laval, Quebec; 29 April 2020. 190. sanofi-aventis U.S. LLC. SARCLISA® full prescribing information. Bridgewater, NJ, USA; March 2020. 191. Bristol-Myers Squibb. IXEMPRA® product monograph. Princeton, New Jersey; 01 October 2007. 192. The United States Pharmacopeia (USP). General Chapter 797: Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: The United States Pharmacopeial Convention, Inc.; 2004. 193. Kastango ES. The ASHP discussion guide for compounding sterile preparations. Bethesda (MD): American Society of Health-System Pharmacists, Inc.; 2004. p. 5.

BC Cancer Chemotherapy Preparation and Stability Chart© version 2.00. All rights reserved. 60/60 This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy. Activation Date: 2 March 2006 Revised Date: 1 September 2021